Patent intelligence · US
US 8969413
Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
Patent details — US 8969413
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 3, 2015
- Expiration
- Feb 26, 2035
- Applicant
- Catalyst Pharmaceuticals, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K31/195, A61K31/197, A61K31/205
Quick answer
US 8969413 (Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid) is held by Catalyst Pharmaceuticals, Inc.. Status: granted. Granted Mar 3, 2015. Expires Feb 26, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Catalyst Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/195, A61K31/197, A61K31/205, A61P, A61P25/00
More from Catalyst Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11806421
Porous-cellulose particles and production method thereof, and cosmetic
granted -
US 11701307
Organic-inorganic composite particles, manufacturing method therefor, and cosmetic
granted -
US 11491212
Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
granted -
US 11401513
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
granted -
US 11384062
Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
granted -
US 11266724
Modified factor VII polypeptides for subcutaneous administration and on-demand treatment
granted -
US 11203749
Factor VII polypeptides that are modified and uses thereof
granted -
US 11020326
Hollow particles and cosmetic
granted
Frequently asked questions
What is US patent 8969413?
US 8969413 (Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid) is held by Catalyst Pharmaceuticals, Inc.. Status: granted. Granted Mar 3, 2015. Expires Feb 26, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8969413?
Catalyst Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 61 pharmaceutical patents for this assignee.
When does US 8969413 expire?
Our index shows an expiration date of Feb 26, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.